Could a simple blood test predict lung danger in heart defect patients?

NCT ID NCT02691689

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study aims to find genes that make some people with congenital heart defects develop a serious lung condition called pulmonary arterial hypertension (PAH). Researchers will analyze DNA from blood samples of 21 patients with heart defects who also have PAH. The goal is to identify genetic mutations that could help predict and prevent PAH in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Genetic testing (DNA sequencing on blood samples)
What this could lead to
If successful, this could lead to a genetic screening tool to identify heart defect patients at risk for pulmonary hypertension, enabling earlier monitoring or prevention.
What could go wrong
This is a small pilot study with only 21 participants, so findings may not apply to everyone. It is exploratory and may not identify clear genetic links.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETIC TESTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospitals Leuven

    RECRUITING

    Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.